CD8+CD25+调节性T细胞在疾病中的研究进展

doi:10.16352/j.issn.1001-6325.2022.12.1939

基础医学与临床 ›› 2022, Vol. 42 ›› Issue (12): 1939-1944.doi: 10.16352/j.issn.1001-6325.2022.12.1939

CD8⁺CD25⁺调节性T细胞在疾病中的研究进展

文李娜, 陈丽, 段瑞, 李芳^*

山西医科大学第二临床医学院风湿免疫科, 山西太原 030000

收稿日期:2021-07-01 修回日期:2021-12-08 出版日期:2022-12-05 发布日期:2022-11-23
通讯作者: ^* sunshine5670@hotmail.com
基金资助:
山西省留学人员科技活动择优资助项目(晋财社{2018}123号);山西省回国留学人员科研资助项目(2016-117)

Progress of CD8⁺CD25⁺regulatory T cells in diseases

WEN Li-na, CHEN Li, DUAN Rui, LI Fang^*

Department of Rheumatology and Immunology,the Second Hospital of Shanxi Medical University, Taiyuan 030000,China

Received:2021-07-01 Revised:2021-12-08 Online:2022-12-05 Published:2022-11-23
Contact: ^* sunshine5670@hotmail.com

摘要/Abstract

摘要： CD8⁺CD25⁺Treg具有抑制免疫反应和诱导免疫耐受作用。本文综述了CD8⁺CD25⁺Treg在恶性肿瘤、自身免疫性疾病及其他常见病如哮喘、过敏性疾病、2型糖尿病、子痫前期中的变化及相应的作用机制,CD8⁺CD25⁺Treg在不同疾病中的变化不一致,在恶性疾病中升高,而在自身免疫性疾病中降低。进一步加深对CD8⁺CD25⁺Treg的认识将为疾病的防治及预后提供依据。

关键词: CD8⁺CD25⁺Treg, CD8⁺Treg, 调节性T细胞, 自身免疫性疾病, 肿瘤

Abstract: CD8⁺CD25⁺Treg can inhibit immune response and induce immune tolerance. This article reviews the changes and underlying mechanisms of CD8⁺CD25⁺Treg in pathogenesis of malignant tumors, autoimmune diseases and other common diseases such as asthma, allergic diseases, type 2 diabetes, and pre-eclampsia. The changes of CD8⁺CD25⁺Treg in different diseases are inconsistent, cell counting increased in malignant diseases but decreased in autoimmune diseases. Further understanding of CD8⁺CD25⁺Treg would supporte a basis for the prevention, treatment and improving prognosis of these diseases.

Key words: CD8⁺CD25⁺Treg, CD8⁺ Treg, regulatory T cells, autoimmune diseases, tumors

中图分类号:

文李娜, 陈丽, 段瑞, 李芳. CD8⁺CD25⁺调节性T细胞在疾病中的研究进展[J]. 基础医学与临床, 2022, 42(12): 1939-1944.

WEN Li-na, CHEN Li, DUAN Rui, LI Fang. Progress of CD8⁺CD25⁺regulatory T cells in diseases[J]. Basic & Clinical Medicine, 2022, 42(12): 1939-1944.

参考文献

[1]Li A, Herbst RH, Canner D, et al. IL-33 Signaling alters regulatory T Cell diversity in support of tumor development[J]. Cell Rep, 2019, 29: 2998-3008.
[2]Cosmi L, Liotta F, Lazzeri E, et al. Human CD8⁺CD25⁺ thymocytes share phenotypic and functional features with CD4⁺CD25⁺ regulatory thymocytes[J]. Blood, 2003, 102: 4107-4114.
[3]周文超, 蔡祥胜, 熊小敏, 等. CD4~+CD25~+CD127~(Low)调节性T细胞在原发性肝癌患者外周血的表达及临床意义[J]. 国际检验医学杂志, 2020, 41: 403-405+409.
[4]Troncone E, Monteleone G. Smad7 and colorectal carcinogenesis: a double-edged sword[J]. Cancers (Basel), 2019,11:612. doi: 10.3390/cancers11050612.
[5]Olguín JE, Medina-Andrade I, Molina E, et al. Early and partial reduction in CD4(+)Foxp3(+) Regulatory T Cells during colitis-associated colon cancer induces CD4(+) and CD8(+) T Cell activation inhibiting tumorigenesis[J]. J Cancer, 2018, 9: 239-249.
[6]陈书平, 巫艳彬, 吴聪. CD8~+CD25~+FOXP3~+调节性T淋巴细胞在恶性胸腔积液中的表达及其临床意义[J]. 中国癌症防治杂志, 2010, 2: 296-300.
[7]Zahran AM, Nafady-Hego H, Mansor SG, et al. Increa-sed frequency and FOXP3 expression of human CD8(+)CD25(High+) T lymphocytes and its relation to CD4 regulatory T cells in patients with hepatocellular carcinoma[J]. Hum Immunol, 2019, 80: 510-516.
[8]Zhang S, Wu M, Wang F. Immune regulation by CD8⁺ Treg cells: novel possibilities for anticancer immuno-therapy[J]. Cell Mol Immunol, 2018 Sep;15:805-807.
[9]卢永红.卵巢癌患者组织及外周血CD8~+T细胞中调节性T细胞相关分子标志物的表达及意义[J].实用癌症杂志,2019,34:1271-1274.
[10]Notley CA, Mccann FE, Inglis JJ, et al. ANTI-CD3 therapy expands the numbers of CD4⁺ and CD8⁺ Treg cells and induces sustained amelioration of collagen-induced arthritis[J]. Arthritis Rheum, 2010, 62: 171-178.
[11]Fischer R, Proske M, Duffey M, et al. Selective activa-tion of tumor necrosis factor receptor Ⅱ induces antiinflammatory responses and alleviates experimental arth-ritis[J]. Arthritis Rheumatol, 2018, 70: 722-735.
[12]Tsai YG, Lee CY, Lin TY, et al. CD8⁺ Treg cells associated with decreasing disease activity after intravenous methylprednisolone pulse therapy in lupus nephritis with heavy proteinuria[J]. PLoS One, 2014,9:e81344. doi: 10.1371/journal.pone.0081344.
[13]Mishra S, Liao W, Liu Y, et al. TGF-β and Eomes control the homeostasis of CD8⁺ regulatory T cells[J]. J Exp Med, 2021,218:e20200030. doi: 10.1084/jem.20200030.
[14]买文丽, 韩清娟, 曹文轩, 等. 人源化NOD小鼠中CD8~+CD25~+Tregs的频率和功能研究[J]. 免疫学杂志, 2016, 32: 7-12.
[15]Zhang M, Wang S, Guo B, et al. An altered CD8(+) T cell epitope of insulin prevents type 1 diabetes in humanized NOD mice[J]. Cell Mol Immunol, 2019, 16: 590-601.
[16]Correale J, Villa A. Role of CD8⁺ CD25⁺ FoxP3⁺ regulatory T cells in multiple sclerosis[J]. Ann Neurol, 2010, 67: 625-638.
[17]Eusebio M, Kraszula L, Kupczyk M, et al. Interleukin-2-mediated stat-5 expression levels in CD8⁺CD25⁺ regulatory T cells: the relevance for asthma[J]. J Biol Regul Homeost Agents, 2019,33:1747-1754.
[18]Tsai YG, Yang KD, Wen YS, et al. Allergen-specific immunotherapy enhances CD8⁺CD25⁺CD137+ regulatory T cells and decreases nasal nitric oxide[J]. Pediatr Allergy Immunol,2019,30:531-539.
[19]Lin L, Dai F, Wei J, et al. Influences of CD8⁺ Tregs on peripheral blood mononuclear cells from allergic rhinitis patients[J]. Laryngoscope, 2021,131:E316-E323.
[20]毛亚静, 陆勤, 奚杰, 等. 内皮细胞微粒与CD8~+ CD25~+ FoxP3~+调节T细胞对子痫前期发生发展的作用探究[J]. 中国计划生育和妇产科, 2019, 11: 57-60.
[21]朱静和,蒋凤,刘青员,等.CD8~+CD25~+FoxP3~+调节T细胞在新诊断2型糖尿病患者外周血中的变化及其临床意义[J].中国糖尿病杂志,2020,28:202-206.
[22]Gupta S, Su H, Agrawal S. CD8 Treg cells inhibit B-cell proliferation and immunoglobulin production[J]. Int Arch Allergy Immunol, 2020,181:947-955.
[23]Churlaud G, Pitoiset F, Jebbawi F, et al. Human and mouse CD8(+)CD25(+)FOXP3(+) Regulatory T Cells at steady state and during Interleukin-2 Therapy[J]. Front Immunol, 2015,6:171. doi:10.3389/fimmu.2015.00171.
[24]Van ZL, Arroyo HR, Côrte-Real BF, et al. Fast and efficient genome editing of human FoxP3⁺ Regulatory T Cells[J]. Front Immunol,2021,12:655122.doi: 10.3389/fimmu.2021.655122.

CD8⁺CD25⁺调节性T细胞在疾病中的研究进展

Progress of CD8⁺CD25⁺regulatory T cells in diseases

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	夏雨佳, 杨振丽, 刘玉琴. 肿瘤类器官临床前转化研究及应用[J]. 基础医学与临床, 2024, 44(9): 1214-1218.
[2]	刘保清, 黄容, 卢艳, 李凯, 张宁, 刘长征, 宋伟. 胃癌类器官在基础研究与临床应用中的进展[J]. 基础医学与临床, 2024, 44(9): 1219-1222.
[3]	李阳, 朱蕾. 真核延伸因子2激酶是治疗肿瘤的潜在新靶标[J]. 基础医学与临床, 2024, 44(7): 1039-1043.
[4]	陈笑天, 陈翀, 罗云萍. MAFB对肿瘤相关巨噬细胞极化及功能的影响[J]. 基础医学与临床, 2024, 44(7): 965-973.
[5]	谭树芬, 何利平, 杨琳琳, 杨谢兰, 杨宏英, 姚明姣, 李树清. TBL与工作坊整合教学法在妇科肿瘤学临床教学中的应用[J]. 基础医学与临床, 2024, 44(7): 1054-1057.
[6]	周玥, 童安莉. 嗜铬细胞瘤/副神经节瘤免疫微环境[J]. 基础医学与临床, 2024, 44(6): 742-747.
[7]	张沥元, 杜函泽, 潘慧. 治疗下丘脑性肥胖的药物研究进展[J]. 基础医学与临床, 2024, 44(5): 729-732.
[8]	王婷婷, 郭丹, 陆君阳, 徐徕, 董海涛, 林佃新, 肖毅. 结直肠神经内分泌肿瘤细胞突变类型分析[J]. 基础医学与临床, 2024, 44(4): 523-527.
[9]	王子豪, 夏小超, 李舜. 跨膜蛋白质在恶性肿瘤中作用的研究进展[J]. 基础医学与临床, 2024, 44(3): 398-402.
[10]	吴玉红, 喻才元, 叶石才. NMES1基因在恶性肿瘤中作用的研究进展[J]. 基础医学与临床, 2024, 44(3): 403-407.
[11]	南璐, 郭梦杰, 高雅楠, 贾红燕. 膜联蛋白A家族成员在乳腺癌中作用机制的研究进展[J]. 基础医学与临床, 2024, 44(3): 393-397.
[12]	陈雪, 罗添, 魏超君. 溶血磷脂酰胆碱酰基转移酶1在肿瘤中作用的研究进展[J]. 基础医学与临床, 2024, 44(2): 256-259.
[13]	刘宛榕, 赵林. 颅内生殖细胞肿瘤的药物治疗[J]. 基础医学与临床, 2024, 44(10): 1350-1356.
[14]	刘林弟, 吕庆杰. GPSM2在肿瘤中作用机制的研究进展[J]. 基础医学与临床, 2024, 44(10): 1447-1450.
[15]	李文超, 李祥生, 李富光, 张志永, 惠磊, 周文科. 长链非编码RNA与疾病[J]. 基础医学与临床, 2024, 44(10): 1465-1469.

CD8+CD25+调节性T细胞在疾病中的研究进展

Progress of CD8+CD25+regulatory T cells in diseases

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

CD8⁺CD25⁺调节性T细胞在疾病中的研究进展

Progress of CD8⁺CD25⁺regulatory T cells in diseases